Lupin Limited · NSE:LUPIN
Lupin — Q1 FY2021 Earnings Presentation
14 slides from Lupin's earnings presentation, Aug 7, 2020
Slide 1: Exchange filing cover letter for Q1 FY2021 Investor Presentation
August 7, 2020 BSE Limited Department of Corporate Services, P. J. Towers, Dalal Street, MUMBAI - 400 001. National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051. Dear Sir/Madam, Sub: Q1 FY2021 Investor Presentation. Pursuant to Regulation 30(
Slide 2: Investor Presentation Q1 FY2021
Investor Presentation Q1 FY2021 August 07, 2020
Slide 3: Safe Harbor Statement
Safe Harbor Statement Materials and information provided during this presentation may contain ‘forward-looking statements’. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to diffe
Slide 4: Lupin – Awards and Accolades
Lupin – Awards and Accolades • McKesson Supplier of the Year Award - 2019 • India Pharma Innovation of the Year 2019 - Department of Pharmaceuticals, Govt. of India • Operational Excellence in Manufacturing – India Pharma 2019 • Lupin’s Ankleshwar Facility Wins Gold Award - American Society for Qual
Slide 5: Q1 FY2021 Snapshot
Q1 FY2021 Snapshot Sales (INR mn, YoY Growth) Important developments Commercial India, North America, Mr. Nilesh.D.Gupta • Amidst the challenges, maintained outperformance Managing Director 12,854, (2%) 12,160, (21%) to IPM1 and further improved market share Lupin Limited • Signed distribution agree
Slide 6: Strategic Vision
Strategic Vision Well Diversified Pharma Business Strong Complex Specialty Foundation Generics Focus Focus Amongst the Top 10 Committed to building Focus on delivering generic companies in a strong specialty high barrier products the World business Sustain and Grow Portfolio Execution Build • Major
Slide 7: Q1 FY2021 Financial Results Review
Q1 FY2021 Financial Results Review
Slide 8: P&L Highlights – Q1 FY2021
P&L Highlights – Q1 FY2021 % of QoQ % of % of YoY Amount in INR mn Q1 FY21 Q4 FY20 Q1 FY20 sales growth salessales growth Net sales 34,686 100.0% 37,910 100.0% (8.5%) 38,155 100.0% (9.1%) Other operating income 593 547 622 Total revenue 35,279 38,457 (8.3%) 38,777 (9.0%) Gross profit 21,807 62.9% 23
Slide 9: North America
Q1FY21 North America 35% YoY 21.1% QoQ 23.0% One-off Metformin recall a setback Consolidating our position in the US1 US quarterly sales ($ mn) #3 #3 140 #4 #3 6 218 212 120 #5 #4 129 5 29.1% average 100 123 126 186 109 4 184 80 market share1 83 3 157 60 79 40 65 63 62 2 44 45 51 20 1 0 0 2015-16 20
Slide 10: India
Q1FY21 India 37% YoY 1.7% QoQ 7.8% India business continues to outperform IPM Leadership across cardiac, diabetes, and respiratory India quarterly Sales (INR bn) IQVIA Q1 FY21 5 Year CAGR% Lupin Rank1 13.1 13.4 13.0 12.9 (YoY % growth) MAT MAT 11.9 Therapy Market Lupin Jun-15 Jun-20 (1.4) Acute 8% 6
Slide 11: Other Markets
Other Markets • Germany: EUR 7.6 mn sales in Q1 FY21 EU5 • ARV’s, Inhalation and CNS are the key focus therapeutic segments Developed • NamusclaTM – Signed distribution agreement in key EU territories • 4th largest generics player3 Australia • Biosimilar Etanercept approved in Australia • 4th larges
Slide 12: Manufacturing and R&D – Diverse Global Network
Manufacturing and R&D – Diverse Global Network Global Commercial Presence 100 23 7 Countries where Countries with Countries with OPERATIONS products are sold marketing offices subsidiaries RESEARCH 15 7 Manufacturing Sites R&D Sites ◼ 12 USFDA inspected sites ◼ 434 US ANDAs; 276 approved ◼ 30 bn+ ex
Slide 13: R&D – Higher focus on complex products and FTFs
R&D – Higher focus on complex products and FTFs Invested INR 3.6 bn or 10.3% of sales on R&D in Q1FY21 at 7 R&D sites globally Optimizing R&D spend US Pipeline 5.0 11.0% 11.5% 12.0% 10.3% 434 cumulative filings 9.5% 9.1% 10.0% 4.0 8.0% 3.0 6.0% 2.0 4.2 4.3 158 pending approval 3.6 3.4 3.6 4.0% 1.0 2
Slide 14: Thank You
THANK YOU VISIT WWW.LUPIN.COM FOR DETAILS FOLLOW US ON